Jay S. Epstein
YOU?
Author Swipe
View article: Generating pathways to domestically sourced plasma‐derived medicinal products: Report from a workshop by the International Plasma and Fractionation Association and the Working Party on Global Blood Safety of the International Society of Blood Transfusion
Generating pathways to domestically sourced plasma‐derived medicinal products: Report from a workshop by the International Plasma and Fractionation Association and the Working Party on Global Blood Safety of the International Society of Blood Transfusion Open
Plasma‐derived medicinal products (PDMPs) are recognized internationally as essential medicines required to treat various acute and chronic conditions including congenital deficiencies of plasma proteins in haemophilia and primary immune d…
View article: Response to comments from the International Patient Organization for Primary Immunodeficiencies on ‘Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low‐ and middle‐income countries’
Response to comments from the International Patient Organization for Primary Immunodeficiencies on ‘Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low‐ and middle‐income countries’ Open
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
View article: Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low‐ and middle‐income countries
Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low‐ and middle‐income countries Open
Industrial plasma fractionation, a complex and highly regulated technology, remains largely inaccessible to many low‐ and middle‐income countries (LMICs). This, combined with the limited availability and high cost of plasma‐derived medicin…
View article: Stepwise access to safe plasma proteins in resource‐constrained countries: Local production and pathways to fractionation—Report of an International Society of Blood Transfusion Workshop
Stepwise access to safe plasma proteins in resource‐constrained countries: Local production and pathways to fractionation—Report of an International Society of Blood Transfusion Workshop Open
Background and Objectives Actions are needed to improve access to safe plasma‐derived medicinal products (PDMPs) in low‐ and middle‐income countries (LMICs). Materials and Methods The International Society of Blood Transfusion (ISBT) Worki…
View article: A <scp>WHO</scp> tool for risk‐based decision making on blood safety interventions
A <span>WHO</span> tool for risk‐based decision making on blood safety interventions Open
Background Risk‐based decision making is increasingly recognized as key to support national blood policy makers and blood operators concerning the implementation of safety interventions, especially to address emerging infectious threats an…
View article: Sources of guidance on collection and use of COVID-19 convalescent plasma especially relevant to low- and middle- income countries
Sources of guidance on collection and use of COVID-19 convalescent plasma especially relevant to low- and middle- income countries Open
Interest in Africa on therapeutic use of COVID-19 convalescent plasma (CCP) has increased with continental spread of the pandemic of SARS -CoV-2. Consequently, blood organisations in several countries have established governmentally approv…
View article: Use of COVID‐19 convalescent plasma in low‐ and middle‐income countries: a call for ethical principles and the assurance of quality and safety
Use of COVID‐19 convalescent plasma in low‐ and middle‐income countries: a call for ethical principles and the assurance of quality and safety Open
The limited clinical data available suggest that convalescent plasma (CP) may have a therapeutic benefit in COVID-19 [1]. Absent any known effective therapy and considering the potential for local production, COVID-19 CP is becoming a glob…
View article: Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma
Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma Open
This document provides the perspective as of April 2020 of the Working Party on Global Blood Safety of the International Society of Blood Transfusion on use of COVID-19 convalescent plasma as an experimental treatment for COVID-19. The doc…
View article: Assuring blood safety and availability: Zika virus, the latest emerging infectious disease battlefront
Assuring blood safety and availability: Zika virus, the latest emerging infectious disease battlefront Open
Threats to blood safety from infectious agents, and subsequent public health action, are hardly novel. Transfusion transmission of Treponema pallidum, the etiologic agent of syphilis, was recognized in the early 20th century soon after the…
View article: Screening of Blood Donations for Zika Virus Infection — Puerto Rico, April 3–June 11, 2016
Screening of Blood Donations for Zika Virus Infection — Puerto Rico, April 3–June 11, 2016 Open
Transfusion-transmitted infections have been documented for several arboviruses, including West Nile and dengue viruses (1). Zika virus, a flavivirus transmitted primarily by Aedes aegypti mosquitoes that has been identified as a cause of …
View article: Maintaining a Safe Blood Supply in an Era of Emerging Pathogens
Maintaining a Safe Blood Supply in an Era of Emerging Pathogens Open
Coming shortly after outbreaks of dengue and chikungunya virus in related locations, the recent outbreak of Zika virus in the southern part of the western hemisphere is yet another reminder that infectious pathogens continue to emerge rapi…